EFG Asset Management North America Corp. Has $2.78 Million Holdings in Krystal Biotech, Inc. (NASDAQ:KRYS)

EFG Asset Management North America Corp. grew its holdings in Krystal Biotech, Inc. (NASDAQ:KRYS) by 30.9% during the fourth quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 17,714 shares of the company’s stock after purchasing an additional 4,185 shares during the period. EFG Asset Management North America Corp. owned about 0.06% of Krystal Biotech worth $2,777,000 as of its most recent SEC filing.

A number of other large investors also recently made changes to their positions in KRYS. Vanguard Group Inc. boosted its stake in shares of Krystal Biotech by 1.0% during the 4th quarter. Vanguard Group Inc. now owns 2,878,451 shares of the company’s stock valued at $450,938,000 after buying an additional 28,707 shares during the period. State Street Corp boosted its position in Krystal Biotech by 9.0% during the third quarter. State Street Corp now owns 1,452,811 shares of the company’s stock valued at $264,455,000 after purchasing an additional 119,936 shares during the last quarter. Geode Capital Management LLC boosted its position in Krystal Biotech by 2.0% during the third quarter. Geode Capital Management LLC now owns 591,631 shares of the company’s stock valued at $107,714,000 after purchasing an additional 11,411 shares during the last quarter. Franklin Resources Inc. grew its stake in Krystal Biotech by 34.2% in the third quarter. Franklin Resources Inc. now owns 243,760 shares of the company’s stock valued at $43,774,000 after purchasing an additional 62,178 shares in the last quarter. Finally, Charles Schwab Investment Management Inc. increased its position in Krystal Biotech by 1.2% in the 4th quarter. Charles Schwab Investment Management Inc. now owns 243,170 shares of the company’s stock worth $38,095,000 after purchasing an additional 2,954 shares during the last quarter. Institutional investors and hedge funds own 86.29% of the company’s stock.

Wall Street Analysts Forecast Growth

Several equities analysts recently weighed in on the stock. HC Wainwright reaffirmed a “buy” rating and set a $221.00 price objective on shares of Krystal Biotech in a research report on Friday, February 28th. Chardan Capital lifted their price objective on shares of Krystal Biotech from $212.00 to $218.00 and gave the company a “buy” rating in a research note on Thursday, February 20th. Citigroup upped their price objective on shares of Krystal Biotech from $206.00 to $215.00 and gave the stock a “neutral” rating in a report on Thursday, February 20th. Jefferies Financial Group assumed coverage on Krystal Biotech in a report on Wednesday, March 5th. They set a “buy” rating and a $245.00 price target on the stock. Finally, Cantor Fitzgerald reaffirmed an “overweight” rating and set a $215.00 price objective on shares of Krystal Biotech in a report on Thursday, February 20th. One investment analyst has rated the stock with a hold rating, six have issued a buy rating and one has given a strong buy rating to the stock. According to MarketBeat, Krystal Biotech presently has an average rating of “Buy” and a consensus price target of $220.00.

Krystal Biotech Trading Down 1.1 %

KRYS opened at $192.30 on Wednesday. The business has a 50 day moving average of $168.54 and a 200-day moving average of $173.68. The stock has a market capitalization of $5.54 billion, a price-to-earnings ratio of 64.31 and a beta of 0.87. Krystal Biotech, Inc. has a 1-year low of $141.72 and a 1-year high of $219.34.

Krystal Biotech (NASDAQ:KRYS) last issued its quarterly earnings results on Monday, February 24th. The company reported $1.52 earnings per share for the quarter, beating analysts’ consensus estimates of $1.29 by $0.23. Krystal Biotech had a net margin of 30.69% and a return on equity of 11.41%. The firm had revenue of $91.10 million during the quarter, compared to the consensus estimate of $91.35 million. During the same period in the prior year, the firm earned $0.30 EPS. The business’s revenue was up 116.4% on a year-over-year basis. Equities analysts predict that Krystal Biotech, Inc. will post 6.14 EPS for the current year.

Insider Activity at Krystal Biotech

In other Krystal Biotech news, insider Suma Krishnan sold 25,000 shares of the company’s stock in a transaction that occurred on Thursday, March 13th. The stock was sold at an average price of $177.79, for a total value of $4,444,750.00. Following the completion of the transaction, the insider now owns 1,463,711 shares of the company’s stock, valued at $260,233,178.69. This represents a 1.68 % decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is available at this link. Also, CAO Kathryn Romano sold 750 shares of the firm’s stock in a transaction that occurred on Thursday, February 27th. The stock was sold at an average price of $175.22, for a total value of $131,415.00. Following the completion of the sale, the chief accounting officer now owns 12,604 shares of the company’s stock, valued at $2,208,472.88. This represents a 5.62 % decrease in their position. The disclosure for this sale can be found here. 14.10% of the stock is owned by corporate insiders.

About Krystal Biotech

Krystal Biotech, Inc, a commercial-stage biotechnology company, discovers, develops, and commercializes genetic medicines for patients with rare diseases in the United States. It commercializes VYJUVEK (beremagene geperpavec-svdt, or B-VEC) for the treatment of dystrophic epidermolysis bullosa (DEB).